Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children

J Pediatr. 1993 Jul;123(1):81-4. doi: 10.1016/s0022-3476(05)81543-4.

Abstract

We studied the immunogenicity of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin (PT-9K/129G), filamentous haemagglutinin, and a 69-kilodalton protein, pertactin, in 30 children aged 12 to 24 months and in 80 infants aged 2 to 4 months. A significant increase of the neutralizing titer and of the titers against pertussis toxin, filamentous hemagglutinin, and pertactin, as determined by enzyme-linked immunosorbent assay, was achieved after three doses of vaccine in all the children; a significant increase of these antibody titers was obtained in 100%, 96.1%, 93.5%, and 98.7% of the infants, respectively.

Publication types

  • Comparative Study

MeSH terms

  • Adhesins, Bacterial*
  • Antibodies, Bacterial / blood
  • Antigens, Bacterial / immunology*
  • Bacterial Outer Membrane Proteins / immunology*
  • Bordetella pertussis / immunology*
  • Child, Preschool
  • Drug Evaluation
  • Hemagglutinins / immunology*
  • Humans
  • Immunization Schedule
  • Immunoglobulin G / blood
  • Infant
  • Neutralization Tests
  • Pertussis Toxin*
  • Pertussis Vaccine / administration & dosage
  • Pertussis Vaccine / immunology*
  • Time Factors
  • Vaccines, Inactivated / administration & dosage
  • Vaccines, Inactivated / immunology
  • Virulence Factors, Bordetella / immunology*

Substances

  • Adhesins, Bacterial
  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Bacterial Outer Membrane Proteins
  • Hemagglutinins
  • Immunoglobulin G
  • Pertussis Vaccine
  • Vaccines, Inactivated
  • Virulence Factors, Bordetella
  • filamentous hemagglutinin adhesin, Bordetella pertussis
  • pertactin
  • Pertussis Toxin